Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals’ recent loss of Bill Ackman’s investment serves as a point of caution for the investors going forward
Considering all of Pershing's efforts to create a turnaround situation with the new management team, BMO Capital Markets believes this "throwing in the towel" at these levels sends a poor signal regarding the road ahead for Valeant
Valeant's shares fell about 10% during aftermarket hours yesterday as Pershing Square sells its final stake in the business
Valeant expects to pay down roughly $350 million of borrowings under the new arrangement
Valeant will continue to decline its revenues and face increasing generic competition in near term, according to Mizuho Securities analyst